Media coverage about Agile Therapeutics (NASDAQ:AGRX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agile Therapeutics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 47.1189313892562 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern’s analysis:
Shares of Agile Therapeutics (NASDAQ:AGRX) traded up 0.22% during mid-day trading on Friday, reaching $4.61. The company’s stock had a trading volume of 119,264 shares. The firm’s market cap is $132.80 million. The company has a 50-day moving average of $4.40 and a 200-day moving average of $3.85. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $7.80.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.02. During the same period in the prior year, the business posted ($0.29) earnings per share. On average, analysts predict that Agile Therapeutics will post ($1.02) earnings per share for the current year.
A number of research firms have weighed in on AGRX. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. HC Wainwright began coverage on shares of Agile Therapeutics in a research report on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target on the stock. Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a research report on Sunday, July 16th. Janney Montgomery Scott reiterated a “buy” rating and set a $13.00 price target on shares of Agile Therapeutics in a research report on Thursday, September 7th. Finally, ValuEngine downgraded shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $10.20.
WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/28/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-agile-therapeutics-agrx-share-price.html.
In related news, Chairman Alfred Altomari bought 10,000 shares of the stock in a transaction that occurred on Friday, August 25th. The shares were bought at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the transaction, the chairman now owns 161,587 shares of the company’s stock, valued at $539,700.58. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.50% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.